Chinese Biopharmaceutical Firm Junshi Biosciences Targets $414M IPO In Hong Kong

Chinese biopharmaceutical company Shanghai Junshi Biosciences Co. has filed for a US$414 million initial public offering in Hong Kong, according to a security filing released today.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY